id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15197 R62329 |
Cohen (Lamotrigine) (Mixed indications), 2023 | Cardiac system malformation | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 0.96 [0.81;1.13] | -/8,339 -/4,866,362 | - | 8,339 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8924 R48249 |
Thomas (Lamotrigine) (Controls unexposed, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.75 [0.09;6.05] C | 1/50 9/340 | 10 | 50 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8920 R35918 |
Diav-Citrin (Lamotrigine), 2017 | Cardiovascular anomalies without chromosomal anomalies | at least 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 2.46 [0.66;9.22] C | 3/114 9/828 | 12 | 114 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8969 R30374 |
Ban (Lamotrigine) (Mixed indications), 2015 | Heart anomaly | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes | 3.33 [1.25;8.89] | 7/273 2,041/257,153 | 2,048 | 273 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8908 R30103 |
Källén (Lamotrigine) (Indications NOS), 2013 | Any cardiac defect | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 0.81 [0.44;1.50] | 10/1,084 16,145/1,575,847 | 16,155 | 1,084 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10292 R37689 |
Vajda (Lamotrigine), 2013 | Cardiac Malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.40 [0.14;13.61] C | 3/315 1/147 | 4 | 315 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8909 R35287 |
Mawer (Lamotrigine) (Controls unexposed, disease free), 2010 | Cardiac Malformations | 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
2.59 [0.10;64.75] C excluded (control group) |
0/37 1/285 | 1 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8910 R35291 |
Mawer (Lamotrigine) (Controls unexposed, sick), 2010 | Cardiac Malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No Matched | 1.11 [0.02;57.36] C | 0/37 0/41 | 0 | 37 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 7 studies | 1.16 [0.78;1.71] | 18,229 | 10,212 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Lamotrigine) (Mixed indications; 2: Lamotrigine) (Controls unexposed, sick; 3: Lamotrigine; 4: Lamotrigine) (Mixed indications; 5: Lamotrigine) (Indications NOS; 6: Lamotrigine; 7: Lamotrigine) (Controls unexposed, sick;
Asymetry test p-value = 0.2907 (by Egger's regression)
slope=-0.0932 (0.1173); intercept=0.6560 (0.5555); t=1.1809; p=0.2907
excluded 8909